Henagliflozin Trial Targets Sarcopenic Obesity in Older Adults With New Diabetes
Older adults with newly diagnosed type 2 diabetes mellitus often carry more than excess weight alone. In China, where the burden of diabetes in older people is especially heavy, overweight and obesity commonly coexist with sarcopenic obesity, a condition marked by increasing fat mass alongside progressive skeletal muscle loss. The clinical problem is not cosmetic. Reduced muscle mass worsens insulin resistance, while excess adiposity compounds metabolic stress and leaves patients vulnerable to falls, functional decline, and worse overall outcomes.
The HABIT-GEMs study is built around that biology. This multicentre, randomised, open-label trial will compare henagliflozin proline tablets with metformin extended-release tablets in geriatric patients with newly diagnosed diabetes, with body composition as the central focus rather than body weight alone. The design reflects a basic clinical truth: two patients can have the same body mass index and very different metabolic risk if one has preserved muscle and the other has lost lean tissue.
Why Muscle and Fat Distribution Matter More Than Scale Weight
Body weight can hide clinically important changes in tissue composition. A therapy that lowers weight by reducing fluid or fat may not have the same bedside value as one that preserves skeletal muscle while improving insulin sensitivity. In older adults, that distinction matters because frailty, impaired mobility, and loss of reserve often emerge before dramatic changes in routine glucose metrics are obvious.
The trial’s endpoint strategy is therefore more nuanced than a standard diabetes study. Investigators will assess skeletal muscle mass and fat distribution, not simply body weight. By focusing on composition, the study is positioned to examine whether an SGLT2 inhibitor-based strategy alters the balance between adipose tissue and lean tissue in a population already at risk for sarcopenic obesity. The biological rationale is straightforward: drugs in this class promote urinary glucose excretion and energy loss, which may reshape fat stores, while metformin remains the established comparator for early type 2 diabetes management.
Trial Design and Measurement Strategy
HABIT-GEMs uses a multicentre, randomised, open-label framework with blinded endpoint assessment and centralised allocation. Those features strengthen internal validity while preserving practical feasibility across sites. The open-label design is unavoidable in a comparison like this, but blinded outcome assessment helps limit bias when investigators interpret the body composition data.
Bioelectrical impedance analysis will be used to measure body composition. It is a pragmatic choice for a multicentre study because it is accessible and repeatable, but it is less precise than imaging-based methods. For that reason, the study leans on consistency and scale rather than ultra-high-resolution phenotyping. The protocol also sets a 24-week follow-up window, long enough to observe short- to mid-term changes in muscle and fat distribution, but too brief to define durable effects on disability, fractures, or long-term metabolic outcomes.
A single visit can miss the physiologic trajectory; a 24-week sequence can still reveal whether the body is moving toward leaner, healthier composition or drifting further into metabolic fragility.
Clinical Logic Behind the Comparator Choice
Metformin extended-release tablets provide an appropriate benchmark because they remain foundational therapy for newly diagnosed type 2 diabetes and are familiar to clinicians managing older adults. Henagliflozin proline tablets, by contrast, bring a different metabolic mechanism to the table. In geriatric patients, the critical question is not only whether glucose control improves, but whether the chosen therapy preserves functional tissue while reducing harmful fat accumulation.
Older adults are not uniform in their metabolic response. Some tolerate modest weight loss well; others experience muscle depletion that may worsen physical resilience. A trial centered on body composition rather than hemoglobin A1c alone reflects that older patients often need treatment plans that account for muscle, mobility, and overall physiologic reserve. The protocol does not claim those benefits in advance. It is designed to test whether a pharmacologic strategy can shift the tissue balance in a more favorable direction than standard therapy.
Strengths, Constraints, and What the Protocol Can Actually Answer
Several features make the study methodologically strong. The multicentre randomised design improves generalisability, especially in a condition as prevalent as type 2 diabetes among older adults. Centralised allocation reduces selection bias, and blinded endpoint assessment protects the core measurements from obvious expectation effects. The inclusion of skeletal muscle mass and fat distribution as outcomes also addresses a gap in many diabetes trials, which still rely heavily on weight change as a surrogate for metabolic health.
The limitations are equally important. Bioelectrical impedance analysis is practical, but it cannot match the precision of imaging-based techniques when it comes to distinguishing subtle shifts in fat and lean tissue. The 24-week horizon will not capture longer-term outcomes such as sustained functional change, hospitalization, or late adverse consequences of altered body composition. In geriatric diabetes care, those events often matter as much as laboratory values, and this protocol cannot resolve them.
Even so, the study asks a clinically relevant question at the right moment in the disease course: when diabetes is newly diagnosed, can treatment influence not just glycemia, but the body’s structural reserve? If the answer differs between henagliflozin and metformin, the implications will extend beyond glycemic control and into how clinicians think about diabetes treatment in older adults with fragile muscle stores and excess adiposity. The protocol does not provide results, but it defines a comparison that is tightly aligned with the biology of aging, insulin resistance, and sarcopenic obesity.